Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/ane.13481 http://scihub22266oqcxt.onion/10.1111/ane.13481 34195984!ä!34195984 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\34195984.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Acta+Neurol+Scand 2021 ; 144 (4): 450-459 Nephropedia Template TP {{tp|p=34195984|t=2021. Medium-term changes in patients with epilepsy during the COVID-19 pandemic |pdf=|usr=}}{{34195984}} gab.com Text Medium-term changes in patients with epilepsy during the COVID-19 pandemic JO: Acta Neurol Scand http://www.kidney.de/pget.php?&tw=1&pmid=34195984 #FOAvip OBJECTIVES: The novel coronavirus disease (COVID-19) pandemic has led to social distancing measures and impaired medical care of chronic neurological diseases, including epilepsy, which may have adversely affected well-being and quality of life of patients with epilepsy (PWE). The objective of this study is to evaluate the impact of the COVID-19 pandemic in the levels of anxiety, depression, somnolence, and quality of life using validated scales in PWE in real-life clinical practice. MATERIALS & METHODS: Self-administered scales of anxiety disorders (GAD-7), depression (NDDI-E), somnolence (Epworth Sleepiness Scale; ESS), and quality of life (QOLIE-31-P) in PWE treated in a Refractory Epilepsy Unit were longitudinally analyzed. Data were collected before the beginning (December 2019 - March 2020) and during the COVID-19 pandemic (September 2020-January 2021). RESULTS: 158 patients (85 from the first round and 73 from the second round) 45.0 +/- 17.3 years of age, 43.2% women, epilepsy duration 23.0 +/- 14.9 years, number of antiepileptic drugs 2.1 +/- 1.4, completed the survey. Significant longitudinal reduction of QOLIE-31-P (from 58.9 +/- 19.7 to 56.2 +/- 16.2, p = .035) and GAD-7 scores (from 8.8 +/- 6.2 to 8.3 +/- 5.9, corrected p = .024) was identified. No statistically significant longitudinal changes in the number of seizures (from 0.9 +/- 1.9 to 2.5 +/- 6.2, p = .125) or NDDI-E scores (from 12.3 +/- 4.3 to 13.4 +/- 4.4, p = .065) were found. Significant longitudinal increase of ESS (from 4.9 +/- 3.7 to 7.4 +/- 4.9, p = .001) was found. CONCLUSIONS: During the COVID-19 pandemic, quality of life and anxiety levels were lower in PWE, and sleepiness levels were raised, without seizure change. Twit Text FOAVip Medium-term changes in patients with epilepsy during the COVID-19 pandemic ????Acta Neurol Scand http://www.kidney.de/pget.php?&tw=1&pmid=34195984 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34195984 #FOAvip English Wikipedia <ref>{{Cite pmid|34195984}}</ref> Medium-term changes in patients with epilepsy during the COVID-19 pandemic #MMPMID34195984 Gonzalez-Martinez A; Planchuelo-Gomez A; Vieira Campos A; Martinez-Dubarbie F; Vivancos J; De Toledo-Heras M Acta Neurol Scand 2021[Oct]; 144 (4): 450-459 PMID34195984show ga OBJECTIVES: The novel coronavirus disease (COVID-19) pandemic has led to social distancing measures and impaired medical care of chronic neurological diseases, including epilepsy, which may have adversely affected well-being and quality of life of patients with epilepsy (PWE). The objective of this study is to evaluate the impact of the COVID-19 pandemic in the levels of anxiety, depression, somnolence, and quality of life using validated scales in PWE in real-life clinical practice. MATERIALS & METHODS: Self-administered scales of anxiety disorders (GAD-7), depression (NDDI-E), somnolence (Epworth Sleepiness Scale; ESS), and quality of life (QOLIE-31-P) in PWE treated in a Refractory Epilepsy Unit were longitudinally analyzed. Data were collected before the beginning (December 2019 - March 2020) and during the COVID-19 pandemic (September 2020-January 2021). RESULTS: 158 patients (85 from the first round and 73 from the second round) 45.0 +/- 17.3 years of age, 43.2% women, epilepsy duration 23.0 +/- 14.9 years, number of antiepileptic drugs 2.1 +/- 1.4, completed the survey. Significant longitudinal reduction of QOLIE-31-P (from 58.9 +/- 19.7 to 56.2 +/- 16.2, p = .035) and GAD-7 scores (from 8.8 +/- 6.2 to 8.3 +/- 5.9, corrected p = .024) was identified. No statistically significant longitudinal changes in the number of seizures (from 0.9 +/- 1.9 to 2.5 +/- 6.2, p = .125) or NDDI-E scores (from 12.3 +/- 4.3 to 13.4 +/- 4.4, p = .065) were found. Significant longitudinal increase of ESS (from 4.9 +/- 3.7 to 7.4 +/- 4.9, p = .001) was found. CONCLUSIONS: During the COVID-19 pandemic, quality of life and anxiety levels were lower in PWE, and sleepiness levels were raised, without seizure change. |*COVID-19[MESH] |*Epilepsy/epidemiology[MESH] |Adult[MESH] |Depression/epidemiology/etiology[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Pandemics[MESH] |Quality of Life[MESH]Medium-term changes in patients with epilepsy during the COVID-19 pand(epmc).pdf DeepDyve Pubget Overpricing